tailieunhanh - Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: A multicentre, randomised controlled openlabel phase II trial

About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). | Stereotactic ablative body radiotherapy SABR combined with immunotherapy L19-IL2 versus standard of care in stage IV NSCLC patients ImmunoSABR A multicentre randomised controlled openlabel phase II trial

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN